Essais liés16clinical trials
VilleMadridlocalisation
PaysSpainlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07282574

Ouvrir le site du centre

Essais cliniques associés

16
MoléculeIndication / populationPhaseNCTTitreStatut
Pleneva TM BGC20-0134 SEP Phase 2 NCT01037907 A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) TERMINATED
Selatogrel Maladie coronarienne Phase 3 NCT04957719 SOS-AMI — Selatogrel Outcome Study in Suspected Acute Myocardial Infarction ENROLLING_BY_INVITATION
BMS-986504 Cancer Phase 2/3 NCT07063745 MountainTAP-29 — A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion RECRUITING
Edoxaban Accident vasculaire cérébral Phase 4 NCT03950076 EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) COMPLETED
Tenecteplase Accident vasculaire cérébral Phase 3 NCT07361302 TENACITY — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well RECRUITING
Vicadrostat Insuffisance cardiaque Phase 3 NCT06424288 A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure RECRUITING
Epcoritamab SEP Phase 2 NCT05660967 EPCORE DLBCL-3 — Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma TERMINATED
RO7268489 SEP Phase 2 NCT07282574 Mintaka — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) RECRUITING
Prasinezumab Parkinson Phase 2 NCT04777331 PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease ACTIVE_NOT_RECRUITING
Tacabrutideg Cancer Phase 1/2 NCT05006716 CaDAnCe-101 — A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies RECRUITING
Inavolisib Cancer Phase 2 NCT07054190 A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer RECRUITING
Elranatamab Cancer Phase 3 NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) RECRUITING
Adagrasib Cancer Phase 3 NCT06875310 A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) RECRUITING
RO7507062 Lupus Phase 1 NCT05835986 A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus ACTIVE_NOT_RECRUITING
Sacituzumab govitecan-hziy Cancer Phase 3 NCT06486441 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) ACTIVE_NOT_RECRUITING
Fenebrutinib SEP Phase 3 NCT04586010 FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) ACTIVE_NOT_RECRUITING